Table 3.
Subgroups analysis for antibiotic resistance in P. aeruginosa isolated from clinical samples other than burn samples
| Subgroups | Number of studies | Heterogeneity test | Egger’s test | Random model | |||||
|---|---|---|---|---|---|---|---|---|---|
| Prevalence (95% CI) (%) | Z | P | Q | P | I2 | T | p | ||
| Imipenem | 7 | 47.5(32.8–62.7) | 0.31 | 0.00 | 352.6 | 0.42 | 96.3 | 0.83 | 0.75 |
| Ciprofloxacin | 8 | 62.4(48.6–74.5) | 1.7 | 0.00 | 406.7 | 0.2 | 96.06 | 1.1 | 0.07 |
| Gentamicin | 7 | 60.5(47.4–72.2) | 1.5 | 0.11 | 288.9 | 0.37 | 95.1 | 0.9 | 0.11 |
| Amikacin | 8 | 57.4(46.4–67.8) | 1.3 | 0.00 | 262.2 | 0.9 | 94.2 | 0.1 | 0.18 |
| Ceftriaxone | 5 | 58.6(29.8–82.5) | 0.56 | 0.00 | 129.8 | 0.72 | 96.9 | 0.37 | 0.57 |
| Ceftazidime | 6 | 57.8(44.4–70.2) | 1.14 | 0.00 | 289.6 | 0.99 | 95.5 | 0.00 | 0.25 |
| Cefepime | 5 | 46.4(26.6–67.4) | 0.32 | 0.00 | 250.9 | 0.34 | 96.8 | 1 | 0.74 |
| Piperacillin/tazobactam | 6 | 50.6(40.4–60.8) | 0.11 | 0.00 | 102.9 | 0.35 | 91.2 | 0.97 | 0.9 |
| Aztreonam | 5 | 48.1(27.9–68.9) | 0.17 | 0.00 | 180.7 | 0.1 | 96.6 | 1.9 | 0.86 |
| Cloxacillin | 3 | 77.4(62.8–87.4) | 3.4 | 0.00 | 32.8 | 0.23 | 90.8 | 1.6 | 0.001 |
| Tobramycin | 6 | 65.8(51.2–77.9) | 2.1 | 0.00 | 160.8 | 0.78 | 95 | 0.28 | 0.035 |
| Ticarcillin | 8 | 55.4(40.1–69.7) | 0.68 | 0.00 | 102.5 | 0.70 | 93.1 | 0.39 | 0.49 |
| Carbenicillin | 3 | 79.9(72.7–85.6) | 6.7 | 0.00 | 2.7 | 0.80 | 28.3 | 0.32 | 0.00 |
| Cefotaxime | 3 | 76.6(72.1–80.6) | 9.7 | 0.00 | 9.6 | 0.96 | 79.3 | 0.05 | 0.00 |
| Norfloxacin | 4 | 57.3(11.5–93.3) | 0.24 | 0.00 | 180.9 | 0.45 | 98.3 | 0.91 | 0.81 |
| Polymyxin B | 3 | 1(1–2.5) | 6.4 | 0.00 | 0.001 | 0.05 | 0.00 | 121 | 0.00 |
| Colistin | 3 | 1(1–1.25) | 4.1 | 0.00 | 0.001 | 0.06 | 0.00 | 102 | 0.00 |
Note: Cl: Confidence interval, Q: Cochran's Q test, P: p value, T: t student test, I2: I-square, Z: Z-value.